Potential offtaker

Which other companies from Japan are actively involved in decarbonization initiatives?
  • Nippon Electric Glass Co., Ltd.
  • Kayama Kogyo Co.,Ltd.
  • Noritz Corporation
  • Fast Retailing Co., Ltd.
  • Eisai Co., Ltd. is a Japanese pharmaceutical company that specializes in the development, manufacture, and sale of pharmaceutical products. Founded in 1941, Eisai has grown to become one of the largest pharmaceutical companies in Japan, with a global presence in over 60 countries. Eisai's mission is to improve the quality of life for patients and their families by creating innovative pharmaceutical products that address unmet medical needs.

    In recent years, Eisai has taken a proactive approach to decarbonisation and corporate energy management. The company recognizes that the pharmaceutical industry is a significant contributor to greenhouse gas emissions, and is committed to reducing its carbon footprint in order to mitigate the impact of climate change. Eisai's decarbonisation strategy includes a range of initiatives aimed at reducing energy consumption, increasing the use of renewable energy, and improving energy efficiency.

    One of Eisai's key initiatives in this area is the adoption of corporate power purchase agreements (PPAs) for renewable energy. PPAs are long-term contracts between a corporate buyer and a renewable energy provider, which guarantee a fixed price for renewable energy over a set period of time. By entering into PPAs, Eisai is able to secure a reliable and cost-effective source of renewable energy, while also supporting the growth of the renewable energy industry.

    Eisai has already signed several corporate PPAs for renewable energy, including a 20-year agreement with a solar power plant in Japan. This PPA will provide Eisai with 1,400 MWh of renewable energy per year, which is equivalent to the energy consumption of approximately 400 households. Eisai has also signed a PPA for wind power in the United States, which will provide the company with 50,000 MWh of renewable energy per year.

    In addition to PPAs, Eisai is also investing in renewable energy infrastructure. The company has installed solar panels at several of its facilities in Japan, which generate a total of 1,200 MWh of renewable energy per year. Eisai is also exploring the use of other renewable energy sources, such as geothermal and biomass, in order to further reduce its carbon footprint.

    Eisai's commitment to decarbonisation and renewable energy is not only driven by environmental concerns, but also by business considerations. The pharmaceutical industry is highly regulated, and companies that are able to demonstrate their commitment to sustainability and social responsibility are more likely to be viewed favorably by regulators, investors, and consumers. By investing in renewable energy and reducing its carbon footprint, Eisai is positioning itself as a leader in the pharmaceutical industry and a responsible corporate citizen.

    Eisai's approach to energy management extends beyond renewable energy and decarbonisation. The company has implemented a range of energy efficiency measures at its facilities, including the installation of LED lighting, the use of energy-efficient HVAC systems, and the optimization of production processes to reduce energy consumption. Eisai has also implemented a corporate energy management system, which allows the company to monitor and analyze its energy consumption in real time, and identify areas for further improvement.

    Eisai's commitment to corporate energy management and decarbonisation is reflected in its sustainability goals. The company has set a target to reduce its greenhouse gas emissions by 30% by 2030, compared to its 2015 baseline. Eisai is also committed to achieving carbon neutrality by 2040, and has developed a roadmap to achieve this goal. The roadmap includes a range of initiatives, such as the expansion of renewable energy, the implementation of energy efficiency measures, and the purchase of carbon offsets.

    In conclusion, Eisai is a Japanese pharmaceutical company that is committed to decarbonisation, renewable energy, and corporate energy management. The company recognizes the importance of reducing its carbon footprint in order to mitigate the impact of climate change, and is taking a proactive approach to achieving this goal. Eisai's adoption of corporate PPAs for renewable energy, investment in renewable energy infrastructure, and implementation of energy efficiency measures demonstrate its commitment to sustainability and social responsibility. By positioning itself as a leader in the pharmaceutical industry and a responsible corporate citizen, Eisai is well positioned to thrive in a rapidly changing business environment.

    ✓ Re100 member
    ✓ Science Based Targets member
    Decarbonization Pathways for Manufacture of basic pharmaceutical products: An Analysis

    Which companies in the industry of Manufacture of basic pharmaceutical products have made significant pledges or efforts to address global warming?
  • Otsuka Holdings
  • Daiichi Sankyo Company, Limited
  • Chiesi Group
  • Nutrition&Santé
  • Apoteket AB